Lipid-derived metabolites play an important role in the regulation of cell responses to external stimuli, including cell growth control, transformation and apoptosis. Phospholipase D (PLD) is one of the critical elements in the regulation of lipid metabolism and the generation of second messengers, some of them involved in cell growth control. Oncogenic Ras proteins aect the activity of PLD by two alternate mechanisms, involving a positive activation and a feedback negative loop. Here we investigate the involvement of the proto-oncogenic Ras protein in the physiological activation of PLD induced by platelet-derived growth factor (PDGF). Overexpression of the wild type Ras protein or some of its regulatory components, such as Shc or Grb2, induces an ampli®cation of PLD activation by PDGF challenge. Furthermore, blocking the endogenous Ras by expression of the dominant negative mutant, H-Ras-Asn 17 completely eliminated the activation of PLD by PDGF. Thus, PDGF requires a complex system for PLD regulation implying the existence of at least two positive regulatory pathways, a Ras-dependent and a PKC-dependent mechanism. These results imply that PLD is an important element in signaling by Ras proteins that is altered after ras-induced transformation. Oncogene (2000) 19, 431 ± 437.
Introduction
Growth factor stimulation leads to the activation of multiple intracellular signal transduction pathways (Cross and Dexter 1991; Goastin et al., 1986) . Mitogenic response requires the simultaneous activation of several of these pathways, although some of them seem to be dispensable or redundant (Nimual et al., 1998; Yuryev and Wennogle 1998) . Moreover, there is a complex crosstalk between distinct signaling pathways and also between molecules located in distant steps of the same pathway (Khosravi-Far and Der 1994; Roux et al., 1997) .
Ras molecules are key elements of many signal transduction pathways initiated at tyrosine kinase receptors (TKRs) as well as G-protein coupled receptors (Cross and Dexter 1991; Der 1994, Rodriguez-Viciana et al., 1997) . Ras proteins are small GTPases that are inactive in its GDP-bound form. Interaction with speci®c exchange factors leads to GDP release and GTP loading. In its GTP form, Ras proteins are able to interact with and activate several eector molecules including the serine/threonine kinase c-Raf-1 (Moodie et al., 1993; Zhang et al., 1993; Vojtek et al., 1993; Warne et al., 1993) , the Ral exchange factor RalGDS (Albright et al., 1993) and the lipid kinase PI3K (Rodriguez-Viciana et al., 1994) .
After growth factor stimulation, several SH2-containing molecules bind to speci®c phosphotyrosines in the growth factor receptor (Schlessinger 1993; Pawson 1998 ). Some of these SH2 molecules are enzymes, and bind only when the receptor is phosphorylated at certain tyrosine residues (Kazlauskas, 1994) . Other small SH2-containing proteins, with no enzymatic activity, act as adaptors and bind in response to phosphorylation of the receptor at multiple tyrosine residues (Yokote et al., 1994) helping activated receptors to interact with other molecules. One such molecule, Grb2, binds to receptor phosphotyrosines and interacts with the Ras exchange factor Sos, driving it to the plasma membrane, leading to Ras activation (Feig, 1994; Gale et al., 1993) . Shc, another SH2-containing molecule is also implicated in Ras activation. Shc interacts with phosphotyrosines in receptor tyrosine kinases and cytoplasmic tyrosine kinases such as Src (Rozakis-Adcock et al., 1992) .
In addition to Ras, other molecules activated by growth factors have an important role in signal transduction. Several phospholipases implicated in phospholipid metabolism and second messenger generation have been identi®ed as targets for TKRs as well as G-protein coupled receptors (Exton, 1994) . Among them, PI-PLC has been extensively studied, and its role in calcium homeostasis and protein kinase C activation is well established (Yeo et al., 1994; Lee et al., 1994) . PLCg isoform is a SH2-containing molecule directly activated by TRKs, while PLCb is activated by activated G-protein coupled receptors. Finally, a large body of evidence indicate that cPLA 2 is a critical enzyme in the regulation of multiple cellular functions through its generation of the lipid-derived second messengers LPA and arachidonic acid (Moolenaar, 1995; Dennis, 1994) . In addition, cPLA 2 is activated by phoshorylation by ERKs, one of the critical enzymes involved in mitogenic signaling (Lin et al., 1993) . Unlike PLC and PLA 2 , type D phospholipases are less well known. Despite lack of precise knowledge about PLD regulation, a great deal of evidence indicates that mammalian PLDs have a role in signal transduction (Frohman and Morris, 1996; Hammond et al., 1995) . Phospholipase D is activated after stimulation with growth factors (Ben-Av and Liscovitch, 1989; Kiss, 1992) , hormones (Freeman and Tallant, 1994; Kiss et al., 1991; Liscovitch and Amsterdam, 1989; Qian and Drewes, 1989) and phorbol esters (del Peso et al., 1996 (del Peso et al., , 1997 Huang and Cabot, 1990) . PLD added exogenously to cells has mitogenic activity, and its activation has been implicated in the transduction of several stimuli and the regulation of diverse biological processes including cell growth and metastasis (Bonser et al., 1989; Carnero and Lacal, 1995; Imamura, et al., 1993; Kondo et al., 1992; Liscovitch and Amsterdam, 1989) .
Despite the evident role of PLD in signal transduction, its regulation either under physiological or pathological conditions is not completely understood. In fact, several molecules has been implicated in PLD activation, including members of the family of small GTP-binding proteins such as Ras (Carnero et al., 1994a,b; Jiang et al., 1995a,b; del Peso et al., 1996; 1997) , ARF (Bourgoin et al., 1995; Brown et al., 1993; Hammond et al., 1995) , Rho (Bowman et al., 1993; Malcolm et al., 1994) and Ral (Jiang et al., 1995b) . The implication of various distinct small GTP-binding proteins in PLD activation most probably re¯ects the existence of several dierent PLD isoenzymes. Indeed, although the cloning of the ®rst mammalian PLDs has been reported (Hammond et al., 1995; Colley et al., 1997) , these do not seem to account for all isoforms described in mammalian cells . In addition to small GTP-binding proteins, PKC (Exton, 1994) , calcium (Exton, 1994) , PI-PLC (Lee et al., 1994; Yeo et al., 1994) , heterotrimeric G proteins and tyrosine phosphorylation have been implicated in PLD activation, highlighting the complexity of PLD regulation and/or variety of PLD isoenzymes. Here we report that normal Ras proteins are involved in the regulation of PLD by PDGF, implying that PLD is a downstream eector of Ras in the physiological response to growth factors.
Results

Dierential eects of wild type and oncogenic Ras proteins on activation of PLD
We have previously demonstrated that ras transformation induces a constitutive increase in basal PLD activity (Carnero et al., 1994a,b; del Peso et al., 1997) . Moreover, oncogenic Ras proteins induce an increased PLD response to phorbol esters, and an attenuation of growth factor induced PLD activity (del Peso et al., 1996 (del Peso et al., , 1997 . These eects can be observed in both NIH 3T3 and Rat-2 cells (del Peso et al., 1996 (del Peso et al., , 1997 , and data not shown). In order to investigate whether Ras proteins were involved in the physiological response of PLD to agonists, cell lines overexpressing either wild type or oncogenic versions of Ras were generated. Overexpression of either normal or mutated Ras proteins was achieved in Rat-2 cells, determined by Western blot using a speci®c Ras antibody (Figure 1a) . When basal levels of PLD activity were determined in these cell lines, unlike oncogenic Ras, overexpression of the normal Ras protein had no signi®cant eect (Figure 1b) . Moreover, the response to phorbol esters was not altered when compared to the parental cells, indicating that the normal Ras protein does not cooperate with protein kinase C for PLD activation under these conditions (Figure 1c) . Similar results were obtained with other independent mass cultures and when NIH 3T3 cells were used as recipient cells (data not shown). These results imply that wild type and oncogenic Ras proteins have dierential eects on PLD regulation. Furthermore, it suggests that transformation by ras oncogenes may be linked to an altered PLD regulation.
Alteration of the PDGF pathway leading to the activation of Ras modi®es the PLD response PKC is implicated in the physiological activation of PLD induced by growth factors (del Peso et al., 1996 (del Peso et al., , 1997 . Moreover, oncogenic Ras cooperates with PKC for PLD activation, but induces the attenuation of PLD response to growth factors (del Peso et al., 1996 (del Peso et al., , 1997 . We next investigated the eect of normal Ras protein in PLD activation induced by growth factors. As shown in Figure 1d , PDGF-induced PLD activity was greatly ampli®ed in cell lines overexpressing wild type Ras compared to that of control cells in a dosedependent manner. Thus, Ras proteins function as a link between PDGFR and PLD.
To further support this ®nding, we investigated PLD activation by PDGF in Rat-2 cells overexpressing Shc (Rozakis-Adcock et al., 1992) or Grb2 (Feig, 1994; Gale et al., 1993) , two adaptor molecules used by PDGFR for Ras activation. As shown in Figure 2 , treatment with PDGF induces an increase in PLD activity in both cell lines overexpressing Shc-or Grb-2 with similar eciency to that found for cells overexpressing wild type Ras. Thus, expression of wild-type Ras or its regulators Shc or Grb-2, sensitizes PLD to PDGF treatment, an indication that Ras proteins are implicated in PLD activation induced by PDGF.
Inhibition of Ras proteins interfere with activation of PLD by PDGF
We next investigated the eects on this pathway by interfering with Ras signaling. If Ras proteins are involved in the regulation of PLD by PDGF, its dominant negative mutant, Ras-Asn 17 (Hong et al., 1990) , should be able to interfere with PLD activation after PDGF treatment. Constitutive expression of the Ras-Asn 17 mutant in ®broblasts is harmful to the cells, due to the absolute requirement of Ras function (Hong et al., 1990) . Thus, cell lines expressing the Ras-Asn 17 mutant under the dexamethasone-inducible promoter were generated. To that end, the Rat 2 cells used here were tested for dexamethasone receptors, and found that these cells lack these receptors (data not shown), making it impossible to use them with the dexamethasoneinducible system. Thus, NIH3T3 cells were used instead and the generated inducible cell line was designated as NIH-Ras-DN. The functionality of the system was tested analysing the activation by PDGF addition of the MAPK/ERK pathway under conditions of no expression or expression of the Ras-Asn 17 mutant. As shown in Figure 3a , when NIH-Ras-DN cells were treated with dexamethasone, a drastic reduction to undetectable levels of PDGF-induced MAPK/ERK activation was observed. This indicates that Ras-Asn 17 interfered eciently with PDGF signaling. As a second control, the eect of dexamethasone on the regulation of PLD by PDGF or phorbol esters in the parental cell line, NIH3T3 cells, was tested. As shown in Figure 3b , similar basal levels of PLD activity as well as of induction of PLD activity were obtained by either PDGF or PDBu, an indication that dexamethasone does not aect PLD regulation by either agonist in these cells. Then, the speci®c action of expression of the dominant negative mutant, Ras-Asn 17 was investigated. As shown in Figure 4a , when cells were tested for PLD activation in response to PDGF, those expressing the Ras-Asn 17 mutant had a drastic reduction of PLD activity to almost undetectable levels over background levels. On the other hand, under similar conditions, a normal PLD response was observed in the same cells without dexamethasone treatment. As a further control of speci®city, both Ras-Asn 17 uninduced and Ras-Asn ) or the mutated (Ras V 12 ) ras genes by standard procedures, and selected with G418 as mass cultures. Expression of either wild type or mutated Ras proteins of derived cells was tested by Western blot using an speci®c anti-Ras (a-Ras) antibody. Cells were grown to con¯uence, lysed and equivalent amounts of cell extracts resolved by electrophoresis (SDS ± PAGE), transferred to nitrocellulose paper and blotted against the a-Ras antibody as described under Materials and methods. 
Discussion
Phospholipase D (PLD), has been implicated in several signal transduction pathways (Bonser et al., 1989; Carnero and Lacal, 1995; Imamura et al., 1993; Kondo et al., 1992; Liscovitch and Amsterdam, 1989) , and is a key enzyme in the generation of second messengers with important biological functions (Exton, 1994; Lacal, 1997) . As for other molecules implicated in signal transduction pathways, PLD is aected after transformation by oncogenes such as ras, src, met and sis with increased basal constitutive levels (Carnero et al., 1994a,b; del Peso et al., 1996 del Peso et al., , 1997 Carnero and Lacal, 1995; Yeo et al., 1994) . Thus, PLD may be an important molecule in signal transduction and its C-glycerol in DMEM supplemented with 10% fetal calf serum. After the labeling period, cells were washed and incubated for 30 min in serum free DMEM supplemented with 0.5% 1-butanol and dierent concentrations of PDGF-BB (0 ± 100 ng/ml). After the stimulation time, the medium was discarded and cells were processed for PLD activation as described under Materials and methods. Data are the mean+variation of two independent experiments in duplicate. (c) Western blot using an anti-Sem5/Grb2 (a-Grb2) antibody. Cells were grown to con¯uence, lysed and equivalent amounts of cell extracts resolved in SDS ± PAGE, transferred to nitrocellulose paper and blotted against an (a-Grb2) antibody as described under 77 M dexamethasone. Cells were then stimulated with PDGF (30 ng/ml) for 18 min, lysed and equivalent amounts of cell extracts resolved in SDS ± PAGE, transferred to nitrocellulose paper and blotted against an a-MAPK antibody as described under Materials and methods. (b) Dexamethasone does not interfere with PDGF-or phorbol esterinduced PLD activation in parental cells. NIH3T3 cells were grown in DMEM supplemented with a glucocorticoid free serum, and labeled for 72 h with 1 mCi/ml 14 C-glycerol. Cells were left untreated, NIH (7), or treated with 5610 77 M dexamethasone, NIH (+20 h) during the last 20 h of the labeling period to induce Ras-Asn 17 expression. Cells were then washed and incubated for 30 min in serum free DMEM supplemented with 0.5% 1-butanol plus PDGF (30 ng/ml) or PDBu (350 nM). Control cells were untreated (Q). Subsequently, the medium was discarded and cells were processed as indicated for PLD activation as described under Materials and methods. Data are the mean+variation of three independent experiments in duplicate alteration could be required for transformation by some oncogenes. However its regulation and activation by extracellular signals remains poorly understood. On this regard, it is well established that mitogenic stimulation by growth factors leads to PLD activation through a PKC-dependent mechanism (del Peso et al., 1996, 1997). Since PI-PLCg is necessary for growth factor-induced PLD activity (Yeo et al., 1994) , it has been suggested that it is the link between growth factor receptors and PKC. In agreement with this hypothesis, classical forms of PKC (which are activated by DAG and calcium, both byproducts of PI-PLC activity), and in particular PKCa, are the PKC isoforms implicated in PLD stimulation (Eldar et al., 1993; Exton, 1994; Jones and Murray, 1995; Liu et al., 1995; del Peso et al., 1996 del Peso et al., , 1997 . All these results indicate that the pathway involving PI-PLCg is necessary for growth factor-induced PLD activation.
Recently, we have shown that ras transformation increases the PLD response to phorbol esters, suggesting either a cooperation between Ras and PKC proteins or some direct eect on PKC (del Peso et al., 1996 (del Peso et al., , 1997 . Activation of PLD by growth factors is mediated by PKC, but in ras-transformed cells this response is strongly attenuated. This eect is not due to unspeci®c impairment of growth factor signaling since neither receptor autophosphorylation nor activation of PI3K and MAPK is signi®cantly aected after ras transformation. However, the most likely cause of a lack of PLD response to growth factors was related to the speci®c blockade of PI-PLCg activation in ras-transformed cells (del Peso et al., 1996 (del Peso et al., , 1997 .
Ras proteins may use PLD as an important signalling molecule in transformation (Carnero et al., 1994a,b; del Peso et al., 1996 del Peso et al., , 1997 . This hypothesis is based on our ®nding that ras-transformed cells show a constitutive increase in PLD activity. This is also accompanied by an increase in basal levels of the generated products, PA and choline, and their derivatives, DAG and phosphorylcholine. The reported eects of oncogenic Ras on basal and agonist-induced PLD activity suggests a role for Ras in PLD activation. However, the implications of the physiological regulation of PLD by Ras proteins after stimulation by growth factors had not yet been investigated. Here we present data demonstrating that in murine ®broblasts, Ras proteins are implicated in PLD activation by growth factors. These results are in agreement with previous observations from our group (Carnero and Lacal, 1993; Lacal and Carnero, 1994; Carnero et al., 1994a,b; del Peso et al., 1996 del Peso et al., , 1997 and others (Jiang et al., 1995a, b) , pointing out a role of Ras proteins in PLD regulation.
Overexpression of wild type Ras or adaptor proteins, such as Shc or Grb2 that are involved in Ras activation induced by growth factor stimulation, showed an ampli®cation of PLD activation after PDGF treatment. Expression of a dominant negative mutant of Ras, RasAsn 17 , under the control of an inducible promoter, drastically reduced PLD activation by PDGF with no eect on PLD activation by phorbol esters. Thus, Ras is required for PLD activation by PDGF, but dispensable for activation of the enzyme by PKC. These results strongly demonstrate that there are two components for PLD activation induced by PDGF, a PKC-dependent and a Ras-dependent. Furthermore, the endogenous Ras protein is an absolute requirement for PLD activation, implying that Ras proteins are structural components connecting growth factor receptors with the generation of lipid-derived second messengers.
The implication of Ras proteins in PLD activation would explain the synergistic cooperation shown by Ras and PKC for PLD activation (del Peso et al., 1996 (del Peso et al., , 1997 . Our results suggest that both proteins, Ras and PKC, may be in parallel pathways for PLD activation, or be part of a unique, consecutive pathway. We also demonstrate that PLD is regulated by PDGF stimulation through two alternative mechanisms involving PKC, and activation of Ras. Both mechanisms must be linked by still unresolved ways, since inhibition of either PKC or Ras-dependent signaling eliminates PDGF-induced activation of PLD (del Peso et al., 1997; this manuscript). A rather complex network of cross talking signals by Ras proteins and dierent members of the PKC family may be involved. Alternatively, PKC may be regulating a speci®c PLD isoenzyme, while Ras proteins may control a dierent PLD isoenzyme. Finally, a synergism or attenuation of PLD may be functional similar to that described already for oncogenic Ras (del Peso et al., 1996 , 1997 Our group was the pioneer in demonstrating that Ras proteins are able to induce PLD activation Lacal, 1993, 1995; Carnero et al., 1994a,b; Lacal and Carnero, 1994) . It has been suggested also that PLD activation induced by v-src is mediated by Ras and that RalA is responsible for the downstream signals connecting Ras and PLD (Jiang et al., 1995a, b) . However the fact that activated RalA does not alter PLD activity (Jiang et al., 1995a ; Lucas et al., data not shown) makes this issue controversial, and deserves further research. Alternatively, it has been demonstrated that members of the Rho family of GTPases, including RhoA, Rac1 and Cdc42, can directly activate PLD (Bowman et al., 1993; Malcolm et al., 1994) . Rho proteins are also known to be a necessary downstream element of Ras transformation (Qiu et al., 1995; Prendergast et al., 1995; Lewobitz et al., 1995) . Therefore, signals connecting Ras and Rho proteins are also candidates to be involved in Rasinduced activation of PLD.
Transformation by oncogenes other than ras, such as sis, met or src, is also associated with the activation of PLD (del Peso et al., 1996 (del Peso et al., , 1997 . In addition to an elevated PLD activity, transformation by ras oncogenes alters the normal regulation of PLD by growth factors and PKC (del Peso et al., 1996 (del Peso et al., , 1997 . In oncogenetransformed cells such as ras, sis, met or src, PLD response to phorbol esters is highly increased whereas growth factors-induced PLD activity is abrogated in ras, src and met, but not in sis-transformed cells. These results indicate that regulation of PLD by growth factors receptors and their intracellular eectors is a complex network of positive and negative signals. If alteration of this network after transformation by oncogenes had critical eects on the transformation process, a better understanding of the regulation of the PLD pathway may provide new targets for anticancer drug design. Here we report that regulation of PLD by growth factors uses and requires, in addition to PKC, a complex network of signals controlled by the endogenous Ras proteins. These results demonstrate that Ras proteins are implicated in PLD activation induced by growth factors. Our ®nding may have important consequences in the search for new molecules as targets for anticancer drug design, since it places PLD as a downstream target for Ras proteins.
Materials and methods
Cell cultures and plasmids
NIH3T3 or Rat-2 cells were grown in DMEM (GIBCO) supplemented with 10% new born calf serum or fetal calf serum respectively (GIBCO), under standard conditions of temperature (378C), humidity (95%) and carbon dioxide (5%). Generation of cell lines overexpressing the indicated genes was carried out by transfection of the indicated cells by the calcium phosphate method. The day before, cells were seeded at a density of 3610 5 cells per 100 mm dishes. Transfections were carried out using 1 ± 5 mg of the indicated DNA and 20 mg of carrier DNA. After 16 h of incubation, or 8 h for Rat-2 cells, cells were washed with saline phosphate buer and fed with DMEM supplemented with 10% serum. One day later, G418 (Gibco) was added to the medium and resistant colonies were grown to generate a mass culture. Each cell line used was generated by independent transfections carrying the proper controls for each. Dierences in basal levels of PLD may be a re¯ection of conditions of selection.
pEXV-V12-Ras carries the activating mutation that codi®es for Val in codon 12 of the human Harvey-ras gene. pEXV-WTRas carries the wild type human Harvey-ras gene with Gly at position 12. When indicated, the pLNCX-Grb2 carrying the Grb2 gene was used. The R2S7 cell line expressing Shc was a generous gift from T Pawson and the plasmid pMMTV H-ras Asn 17 from L Feig.
Assay of PLD activity
Activation of PLD can be accurately measured by its transphosphatidylating activity on butanol to generate phosphatidylbutanol as previously described (Carnero et al., 1994a,b) . Shortly: cells were grown in 6-well plates and labeled for 48 ± 72 h in the presence of 1 mCi/ml [U-14 C]-Glycerol. After this period, label media was discarded, cells washed with TD buer (137 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 20 mM Tris, pH 7.4) and incubated 30 ± 45 min in serum-free DMEM supplemented with 0.5% 1-butanol in the presence of the indicated agonists. Cells were then scraped in 1 ml methanol, and plates washed once with 0.5 ml of methanol. The two methanol samples were collected and mixed to 2 ml chloroform and 1 ml of water. The organic phases were dried in a 378C heating block under a nitrogen stream and the lipids separated by thin layer chromatography (TLC) using silica gel 60A plates (Whatman, LK6D). The plates were developed with the upper phase of a mixture of ethyl acetate/iso-octane/glacial acetic acid/water (90 : 50 : 20 : 100) plus 1 ml of acetic acid. Plates were visualized and quanti®cated using an electronic autoradiography system (InstantImager, Packard). Counts in phosphatidylbutanol (PtdBut) were normalized for the radioactivity incorporated into total lipids.
Analysis of protein levels by Western-blot
Cells were grown in standard conditions in 100 mm dishes. Culture media was removed, cells washed with TD buer (137 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 20 mM Tris, pH 7.4), and 300 ml of ice-cold lysis buer (50 mM Tris, pH 7.4, 0.25% NP-40, 0.25% SDS, 150 mM NaCl, 15 mM bGlycerophosphate, 10 mM Na PPi, 50 mM Na F, 10 mg/ml aprotinin, 1 mM PMSF) was added. Nuclei and detergentinsoluble material were removed by centrifugation at 13 000 r.p.m. for 20 min at 48C. The resulting supernatants were assayed for estimation of total cell protein (Bio-Rad), and equal amounts of cell lysates (50 ± 100 mg) were boiled at 958C for 5 min in SDS ± PAGE sample buer. For Western blot analysis, proteins were electrophoresed onto 8% (MAPK) or 12% (Ras and Grb2) SDS ± PAGE gels poured in 20620 cm glass plates. Resolved proteins were transferred to nitrocellulose, and blots were blocked for 1 h in 3% non-fat dried milk in T-TBS (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20). Blots were washed once in T-TBS, and incubated for 2 h with an anti-MAPK polyclonal antibody or a polyclonal sera raised against H-Ras (sc-520, Santa Cruz Biotechnology) and developed by ECL (Amersham, UK).
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